Key facts
- It has raised $50.0M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Legend Capital, CDH Investments, Hillhouse Investment Group, Linear Capital, Eastern Bell Venture Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Stonewise
- ·The full record, as it builds
Funding rounds
No funding rounds for Stonewise are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stonewise
Manufacturer of an artificial intelligence drug discovery system designed to accelerate and improve the early stages of pharmaceutical development. The company offers integrated AI-driven capabilities such as pocket finding, molecular generation, ultra-high throughput virtual screening, rational design, and druggability optimisation, enabling pharmaceutical researchers and biopharmaceutical companies to advance from hit identification to preclinical candidate optimisation with greater speed and efficiency.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- stonewise.ai/
- Ownership
- Privately Held (backing)
Stonewise doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stonewise shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stonewise in its N-PORT filings yet. We sweep new filings monthly.